Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database.
Liao W. et al, (2023), EClinicalMedicine, 59
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Dijokaite-Guraliuc A. et al, (2023), Cell Rep, 42
Evaluation of QuantiFERON SARS-CoV-2 interferon- release assay following SARS-CoV-2 infection and vaccination.
Johnson SA. et al, (2023), Clin Exp Immunol
Pan-genotypic probe-based enrichment to improve efficiency of Hepatitis B virus sequencing
Lumley SF. et al, (2023)
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Moore SC. et al, (2023), Med (N Y)
Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK.
Hamill V. et al, (2023), Liver Int
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study.
Flower B. et al, (2023), Elife, 12
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
Green C. et al, (2023), Clin Exp Immunol
Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
Campbell C. et al, (2023), Wellcome Open Research, 7
Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses
Hornsby H. et al, (2023)
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
Sy A. et al, (2023), PLoS One, 18
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.
Murray SM. et al, (2022), Nat Rev Immunol, 1 - 13
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.
Huo J. et al, (2022), Cell Rep
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
Brevini T. et al, (2022), Nature
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes.
Baldelli L. et al, (2022), Gut Liver
SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study.
Ward V. et al, (2022), BMJ Open, 12
Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects.
Mazouz S. et al, (2022), PLoS Pathog, 18
Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch® database: research protocol and statistical analysis plan.
Liao W. et al, (2022), Diagn Progn Res, 6
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Fidler S. et al, (2022), Clin Infect Dis